Track MLTX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
MoonLake Immunotherapeutics
Dorfstrasse 29, Zug, Switzerland, 6300
IPO
2020
Employees
130
Industry
Biotechnology
Sector
Healthcare
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20262-2
0
Q1 20261-1
0
Q4 20254-4
0
Q3 20252-2
0
4-quarter cumulative
9 sells0 buys
Analyst Ratings
4 analysts covering
Buy100%recommend buy
Buy
4
Hold
0
Sell
0